Thomas McGonigal

TL;DR: ABT-888 is a potent inhibitor of PARP, has good oral bioavailability, can cross the blood-brain barrier, and potentiates temozolomide, platinums, cyclophosphamide, and radiation in syngeneic and xenograft tumor models.

TL;DR: The development of a series of potent and selective indazole-pyridine based Akt inhibitors is reported, which inhibit Akt-dependent signal transduction in cells and in vivo in a dose-responsive manner and slow the progression of tumors when used as monotherapy or in combination with paclitaxel or rapamycin.

TL;DR: It is demonstrated that in the presence ofsurvivin, Aurora-B phosphorylates histone H3 much more efficiently than in the absence of survivin in a cell-free system, thus providing a mechanism as to how survivin exerts its function in human cells.

TL;DR: Loss of Bgl2p function renders cells more dependent on chitin for wall integrity, and attenuates virulence (probably due to subtle changes in wall structure), and indicates that additional 1,3-beta-glucosyltransferases are present in the C. albicans BGL2 disruptant.

TL;DR: It is suggested that cancer cells upregulate the homologous recombination DNA repair pathway to compensate for the loss of base excision repair, which may account for the observed resistance to treatment with TMZ and ABT-888.